Abstract Number: 2755 • 2019 ACR/ARP Annual Meeting
Assessing the Sensitivity to Change of the OMERACT Ultrasound Structural Gout Lesions During Urate-Lowering Therapy
Background/Purpose: To evaluate the sensitivity to change of ultrasound (US) structural gout lesions, as defined by the OMERACT US group, in gout patients during urate…Abstract Number: 2834 • 2019 ACR/ARP Annual Meeting
Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study
Background/Purpose: Hyperuricemia is common in patients with type 2 diabetes mellitus and is associated with an increased risk of gout. Sodium-glucose cotransporter 2 (SGLT2) inhibitors,…Abstract Number: 2835 • 2019 ACR/ARP Annual Meeting
A Burden of Missense Genetic Variants in Urate Secretory Genes Is Associated with Inadequate Response to Allopurinol in People with Gout
Background/Purpose: Current understanding of why the urate lowering effect of allopurinol varies among individuals with gout is limited. The rs2231142 (Q141K) variant of ABCG2 is…Abstract Number: 2836 • 2019 ACR/ARP Annual Meeting
Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank
Background/Purpose: Both serum urate-associated genetic variants and body mass index (BMI) are associated with gout risk. The aim of this study was to systematically examine…Abstract Number: 2838 • 2019 ACR/ARP Annual Meeting
The First Phase 2a Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout
Background/Purpose: Acute gout is a severe debilitating type of arthritis that is treated in the acute phase with potent anti-inflammatory drugs. To date, prednisolone, colchicine…Abstract Number: 2839 • 2019 ACR/ARP Annual Meeting
Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts
Background/Purpose: This study aimed to determine whether a polygenic risk score (PRS) based on gout-associated genetic variants is associated with gout disease severity phenotypes such…Abstract Number: 2889 • 2019 ACR/ARP Annual Meeting
From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
Background/Purpose: Gout affects >4 million US adults aged ≥ 65 years, but little is known about the scale and drivers of public spending on gout…Abstract Number: 2892 • 2019 ACR/ARP Annual Meeting
Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
Background/Purpose: To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from…Abstract Number: L01 • 2018 ACR/ARHP Annual Meeting
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In…Abstract Number: 184 • 2018 ACR/ARHP Annual Meeting
Development of Focused Musculoskeletal Ultrasound Training for Primary Care Providers to Facilitate the Diagnosis of Gout: Initial Steps in an Educational Needs Assessment
Background/Purpose: Gout is common in primary care settings, though establishing or excluding the diagnosis with confidence can be challenging, particularly if arthrocentesis is not feasible…Abstract Number: 194 • 2018 ACR/ARHP Annual Meeting
A Survey on Gout-Related Knowledge Among Internal Medicine Residents
Background/Purpose: The prevalence of gout has risen in recent decades despite advancements in therapeutic options due to several reasons, including lack of adherence to treatment…Abstract Number: 197 • 2018 ACR/ARHP Annual Meeting
Improving Clinical Decisions for Gout Management: Effect of Online Case-Based Education
Background/Purpose: Gout is a chronic condition with a considerable effect on patient health and quality of life. Despite the availability of multiple pharmacologic treatments and…Abstract Number: 268 • 2018 ACR/ARHP Annual Meeting
The Effect of Renaming Gout to Urate Crystal Arthritis on Illness and Treatment Perceptions in Māori (the Indigenous People of Aotearoa/New Zealand)
Background/Purpose: Recent research has suggested that renaming gout to a pathophysiological illness label (urate crystal arthritis) avoids inaccurate lay perceptions of gout and promotes…Abstract Number: 410 • 2018 ACR/ARHP Annual Meeting
Experience of Finding Footwear and Factors Contributing to Footwear Choice in People with Gout
Background/Purpose: Gout frequently affects the foot, particularly the first metatarsophalangeal joint and Achilles tendon. People with gout commonly wear ill-fitting footwear that lacks cushioning and…Abstract Number: 860 • 2018 ACR/ARHP Annual Meeting
Efficacy of a Web-Based Module to Educate Internal Medicine Housestaff on Gout
Background/Purpose: Gout is a leading form of inflammatory arthritis. There is a paucity of data that examines the efficacy of teaching internal medicine (IM) residency…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »